Arcellx, Inc. Common Stock (ACLX)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Arcellx, Inc. Common Stock (ACLX) was listed on Nasdaq from February 4, 2022 and stopped trading under the symbol ACLX on April 29, 2026.
- Listed On
- Nasdaq
- Listed Since
- February 4, 2022
- Stopped Trading
- April 29, 2026
- Employees
- 209
About Arcellx, Inc. Common Stock
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 3 institutions reported holding ACLX, with 30,013 shares worth $3.4 million in aggregate. The largest reported holder was Dekabank Deutsche Girozentrale, with 30,000 shares worth $3.4 million. Of the 3 largest holders listed below, 1 added shares, 1 held its position unchanged and 1 sold out during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Dekabank Deutsche Girozentrale | 30,000 | $3M | Unchanged |
| Ifp Advisors | 13 | $1K | Added 8.33% |
| Janus Henderson (Jupiter Topco) | Sold out |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is ACLX?
Arcellx, Inc. Common Stock (ACLX) was listed on Nasdaq from February 4, 2022 and stopped trading under the symbol ACLX on April 29, 2026.
Who are the largest institutional holders of ACLX?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of ACLX were Dekabank Deutsche Girozentrale, Ifp Advisors and Janus Henderson (Jupiter Topco).
How many institutions own ACLX?
3 institutions reported a position in ACLX for the quarter ended June 30, 2026, worth $3.4 million in total.
Did institutions buy or sell ACLX last quarter?
Of the 3 largest reported holders, 1 added shares, 1 held its position unchanged and 1 sold out during the quarter. Every reported holder and its change is on the SentiSense ownership page for ACLX.
Every reported institutional holder, plus insider and congressional trades in ACLX, on SentiSense.